|1.||Spinal Cord Injuries (Spinal Cord Injury)
|2.||Vesico-Ureteral Reflux (Vesicoureteral Reflux)
|4.||Urinary Tract Infections (Urinary Tract Infection)
|5.||Spinal Dysraphism (Spina Bifida)
|1.||Vaidyanathan, Subramanian: 9 articles (01/2012 - 04/2002)|
|2.||Soni, Bakul M: 8 articles (01/2010 - 04/2002)|
|3.||Chancellor, Michael B: 7 articles (09/2009 - 01/2003)|
|4.||Chartier-Kastler, Emmanuel: 6 articles (05/2013 - 09/2004)|
|5.||Denys, Pierre: 6 articles (06/2012 - 09/2004)|
|6.||Singh, Gurpreet: 6 articles (01/2012 - 04/2002)|
|7.||Hughes, Peter L: 6 articles (01/2010 - 01/2007)|
|8.||Soni, B M: 6 articles (03/2006 - 06/2000)|
|9.||Vaidyanathan, S: 6 articles (03/2006 - 06/2000)|
|10.||Singh, G: 6 articles (03/2006 - 06/2000)|
|1.||oxybutynin (Tavor)FDA LinkGeneric
11/01/2006 - "Oxybutynin is extremely safe and effective in almost every population including children, the elderly, and those who have neurogenic bladder. "
01/01/2004 - "A few noncomparative studies have shown promising results with oxybutynin ER in the treatment of adult and paediatric patients with neurogenic bladder dysfunction secondary to neuronal injury. "
03/01/1988 - "The present long-term trial proved that oxybutynin hydrochloride is an exceedingly effective and safe agent for clinical management of unstable bladder and overactive neurogenic bladder."
01/01/2005 - "All 3 formulations of oxybutynin are safe and effective in children with neurogenic bladder dysfunction."
07/01/1990 - "The clinical efficacy of oxybutynin hydrochloride was studied on 21 patients with neurogenic bladder or unstable bladder complaining of urinary frequency, urgency and urgent incontinence. "
|2.||Botulinum Toxins (Botulinum Toxin)IBA
01/01/2013 - "Nonhuman studies, pediatric trials, and those involving patients with neurogenic bladder dysfunction (with the exception of studies involving botulinum toxin A) were excluded. "
06/01/2012 - "Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment."
02/01/2012 - "[Botulinum toxin for neurogenic bladder dysfunction]."
01/01/2012 - "[Repeated injection of botulinum toxin a in patients with neurogenic bladder: our experience]."
01/01/2012 - "The key words used were botulinum toxin A, neurogenic bladder, and children. "
|3.||Type A Botulinum Toxins (Botulinum A Toxin)FDA Link
06/01/2011 - "While retaining efficacy, the endo-injector needle technique appears to be more rapid than the standard procedure for botulinum toxin type A injection for neurogenic bladder dysfunction. "
06/01/2011 - "Botulinum toxin type A has revolutionized the treatment of neurogenic bladder dysfunction. "
01/01/2008 - "Botulinum-A toxin in useful in children with neurogenic bladder overactivity."
01/01/2008 - "[Endoscopic augmentation of neurogenic bladder with botulinum-A toxin in children]."
12/01/2007 - "Between March 2004 and February 2006 a total of 23 children (mean age 5.6 +/- 2.5 years) with neuropathic bladder refractory to medical treatment underwent cystoscopic treatment with botulinum-A toxin. "
|4.||Cholinergic Antagonists (Anticholinergics)IBA
11/01/1990 - "We conclude that anticholinergics are safe and effective, even in the neonatal period, when used in combination with clean intermittent catheterisation for the treatment of neonates with neurogenic bladder dysfunction."
11/01/2010 - "Anticholinergics could be helpful in particular phases of MS. However, there is inadequate evidence currently available on the use of anticholinergics in MS, and further research on the management of the MS neuropathic bladder is warranted."
11/01/1998 - "Neurogenic bladder may require intermittent catheterization or cholinergic therapy; those with hypertonic bladder may benefit from anticholinergics. "
12/01/1996 - "The current management of neurogenic bladder, based on fluid restriction, anticholinergic agents, intermittent self-catheterization, and, in some cases, surgical intervention, often fails to relieve all symptoms. "
01/01/1995 - "Topical oxybutynine (Oxy) has been used successfully in neurogenic bladder patients who remained wet on oral anticholinergics or could not tolerate oral medication. "
07/13/2010 - "[Clinical study of resiniferatoxin on neurogenic bladder]."
11/01/2015 - "Resiniferatoxin (RTX) is used as an experimental drug in therapy of neurogenic urinary bladder disorders. "
07/13/2010 - "To understand the effect of resiniferatoxin on neurogenic bladder by intravesical filling. "
12/01/2001 - "Intravesical instillation of resiniferatoxin for neurogenic bladder dysfunction in a patient with myelodysplasia."
01/01/2003 - "The effect of intravesical capsaicin and resiniferatoxin in neurogenic bladder dysfunction."
04/01/1977 - "In 16 patients with neurogenic bladder dysfunction it was found that a response of more than 0.8 nomogram units indicates a likelihood of clinical improvement with phenoxybenzamine therapy. "
08/01/1980 - "The efficacy of alpha-adrenolytic treatment with oral phenoxybenzamine chloride (40 mg per day during three to four months) has been assessed both clinically and urodynamically among 249 patients with neurogenic bladder function. "
09/01/1999 - "It was used as an adjunct in the management of neuropathic bladder dysfunction that caused failure of the bladder to empty, by tapping or crede to achieve satisfactory residual urine volume of < 100 mL. Phenoxybenzamine was started with a dose of 10 mg daily, increased by 10 mg every 3 days to a dose of 30 mg daily; this was maintained from 3 weeks to 6 months (mean: 39 days). "
03/01/1988 - "The most significant changes resulting from the application of Dibenzyran were observed in the neuropathic bladder with a reduction of the functional urethral length from 24.3 to 20.5 mm and a decrease of Pura max from 100.5 to 82.7 cm H2O. "
01/01/1978 - "[Treatment of neurogenic bladder disorders in 100 quadriplegics with the alpha receptor blocker Dibenzyran]."
|7.||Capsaicin (Zostrix)FDA Link
01/01/2014 - "We conclude that capsaicin and RTX do appear to provide some acceptable treatment results in patients with neurogenic bladder, though larger studies are needed to confirm this. "
01/01/2012 - "Interestingly, the bladder's sensitivity to noxious chemicals has been used successfully in clinical practice, by intravesically infusing the TRPV1 agonist capsaicin to treat neurogenic bladder overactivity. "
09/01/1999 - "The value of intravesical capsaicin in neurogenic bladder hyperactivity has been clearly demonstrated. "
12/01/1997 - "The C-fiber afferent neurotoxin capsaicin, administered intravesically, has been useful in treating certain types of neurogenic bladder overactivity. "
06/11/1994 - "Intravesical capsaicin for treatment of neurogenic bladder."
05/01/2003 - "Intrathecal baclofen did not modified significantly neurogenic bladder dysfunction from spinal lesion. "
10/01/2004 - "Medications, which are prescribed for neuropathic bladder, and the method of bladder drainage, may need suitable changes, as discontinuation of intrathecal baclofen therapy can result in reappearance of detrusor-sphincter dyssynergia in previously susceptible patients."
12/01/1992 - "Continuous intrathecal baclofen may represent a novel approach to the management of patients with a neurogenic bladder who have decreased bladder compliance and detrusor hyperreflexia not controlled by oral medications."
10/01/1992 - "These findings may indicate that a change in pattern of prescription is warranted and that a reliable and practical measurement of systemic baclofen levels has a useful role in clinical practice, particularly for the patient with neurogenic bladder and potential renal insufficiency."
09/01/2004 - "Data derived from conservative management of these disorders in neurogenic bladders: urethral dilatation, various sphincterotomies, bladder disafferentation, alpha-blockers, vanilloids (resiniferatoxin and capsaicin), intra-detrusor botulinum toxin and intrathecal baclofen, have demonstrated a marked improvement of disorders of compliance associated with neurogenic bladder 3). "
|9.||Anti-Bacterial Agents (Antibiotics)IBA
03/01/2004 - "We present here a long-term observation of 2 children with a rare syndrome with a non-neurogenic neurogenic bladder dysfunction (Hinman's syndrome), and we investigated the safety and efficacy of long-term use of terazosine in association with prophylactic antibiotics, timed voiding and a bowel regimen. "
08/01/1999 - "Therefore, routine use of urine cultures or prophylactic antibiotics before urodynamic studies in pediatric patients with a neurogenic bladder does not appear to be indicated."
03/01/1991 - "In addition to multiple courses of empiric antibiotics, the neurogenic bladder and alteration in cell-mediated immunity found in spinal cord injured patients may have increased this patient's susceptibility to fungal disease. "
06/01/1983 - "A previous report indicated that 62 per cent of 200 children with reflux and a neurogenic bladder either ceased to have reflux or reflux was downgraded while on intermittent catheterization and chronic antibiotics. "
11/01/2011 - "Despite using prophylactic antibiotics after the 1st month of kidney transplantation in all 5 patients with neurogenic bladder, they all experienced recurrent UTI. "
10/01/1990 - "The therapeutic utility of bunazosin hydrochloride was evaluated by a multi-center (67 hospitals) double-blind controlled study in patients who complained of voiding disturbances due to neurogenic bladder. "
09/01/1987 - "[Clinical study of bunazosin hydrochloride, an alpha 1-adrenergic blocker, in benign prostatic obstruction and neurogenic bladder dysfunction]."
02/01/1992 - "Bunazosin hydrochloride (Ea-0643), a selective alpha 1-blocker, was administered to 14 patients with neurogenic bladder over prolonged periods of time in order to determine its efficacy and safety. "
02/01/1992 - "[Usefulness and safety of bunazosin hydrochloride in neurogenic bladder after prolonged administration]."
10/01/1990 - "[Clinical evaluation of bunazosin hydrochloride for the treatment of voiding disturbances due to neurogenic bladder--a double-blind study]."
|1.||Intermittent Urethral Catheterization
11/01/1989 - "Clean intermittent catheterization has been an effective treatment for the management of patients with a neurogenic bladder during the last 15 years. "
05/01/2014 - "Clean intermittent catheterization has been demonstrated to be a safe and effective method of bladder drainage in patients with neurogenic bladder dysfunction. "
04/01/2006 - "During an observational prospective study, we determined the safety and efficacy of a weekly oral cyclic antibiotic (WOCA) regimen to prevent UTI in SCI adult patients with neurogenic bladder undergoing clean intermittent catheterization. "
06/01/2005 - "In the neuropathic bladder group the bladder function improved following closure of CV and commencement of anticholinergic medication and clean intermittent catheterization (CIC). "
06/01/1997 - "In addition to any psychological benefit, early intervention with clean intermittent catheterization in children with neurogenic bladder dysfunction may help to prevent irreversible bladder dysfunction and limit the need for bladder augmentation."
12/01/2007 - "Ureteric reimplantation during BA is safe and effective for treating HVUR in patients with neurogenic bladder."
05/01/2015 - "Simultaneous reimplantation may be not necessary during SBA in neurogenic bladder."
09/01/2014 - "SBA alone, without ureteral reimplantation, seemed sufficient for neurogenic bladder. "
07/01/2014 - "Robotic augmentation ileocystoplasty with bilateral ureteric reimplantation in a young child with neuropathic bladder."
08/01/2012 - "Sigmoidocolocystoplasty with ureteral reimplantation for treatment of neurogenic bladder."
|3.||Urinary Diversion (Ileal Conduit)
05/01/2005 - "AC and urinary diversion provide a safe and effective long-term therapy in patients with refractory neurogenic bladder but stomal problems in patients with continent diversion continue to be a source of complications."
02/01/2000 - "Urinary diversion and orthotopic bladder substitution in children and young adults with neurogenic bladder: a safe option for treatment?"
07/01/2013 - "Children < 18 years of age undergoing urinary diversion/reconstruction with Yang-Monti's procedure for congenital conditions or neuropathic bladder formed the study group. "
11/01/2011 - "The objective of this study was to evaluate the impact of ileal conduit urinary diversion on the QoL of patients with neurogenic bladder dysfunction. "
10/01/1994 - "Four patients, two boys and two girls aged between 8 and 16 years, with a neuropathic bladder and incontinence, and one boy, aged 16 years, with an ileal conduit were included in the study. "
|4.||Cystostomy (Suprapubic Cystostomy)
02/01/2009 - "The results of this study have demonstrated that the ileocystoplasty with umbilical continent vesicostomy fullfill with treatment objective's of patients with neurogenic bladder: restoration of continence and improved quality of life by granting them social life."
01/01/2008 - "This study demonstrated that permanent cutaneous vesicostomy is an optimal refinement method for management of the neurogenic bladder in canines. "
09/01/2007 - "The results of this study have demonstrated that Casale Spiral Monti vesicostomy can have dramatic positive effects on the quality of life in adults with a neurogenic bladder by granting them social independence, convenient bladder management, and excellent continence rates."
03/01/2013 - "Suprapubic cystostomy (SPC) catheterization is a common and important technique for the management of vesicular drainage, especially in patients with neurogenic bladder. "
11/01/2011 - "To report our experience with the Lowsley retractor method for suprapubic cystostomy (SPC) in patients with neurogenic bladder (NGB). "
01/01/2013 - "All randomised and quasi-randomised controlled trials comparing methods of using catheters to manage urinary voiding in people with neurogenic bladder. "
11/01/2012 - "The study objectives were to describe the current catheterization habits of the French neurogenic bladder patients using intermittent catheterization (IC), and to evaluate the ease of use, reliability and patients' comfort and patients' acceptance of the new 'no-touch', presumably easy-to-use VaPro catheter. "
11/01/2012 - "Simultaneous suprapubic catheter placement raised the mortality rate in group 1 in comparison with group 2. Repeated urodynamic study in group 4 showed hypertonic behavior in the bladder 10 d after SCI, with significantly increased leak point pressure and bladder capacity; however, the end filling pressure and constant neuropathic bladder on cystometric indices are attained from 20 d after the operation. "
07/01/2011 - "Safety of a new compact catheter for men with neurogenic bladder dysfunction: a randomised, crossover and open-labelled study."
01/01/2011 - "All randomised and quasi-randomised controlled trials comparing methods of using catheters to manage urinary voiding in people with neurogenic bladder. "